Dr Svoboda on the Efficacy of Armored huCART19-IL18 in R/R Lymphoma

Jakub Svoboda, MD, discusses outcomes with armored huCART19-IL18 in patients with previously treated relapsed/refractory lymphomas that have progressed.

Jakub Svoboda, MD, associate professor, medicine, Hematology-Oncology, attending, the Hospital of the University of Pennsylvania; co-chair, Lymphoma Tumor Board and Case Conference; member, Data Safety Monitoring Committee, Abramson Cancer Center, discusses the observed safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed following treatment with an anti-CD19 CAR T cell therapy.

At the 2024 ASCO Annual Meeting, Svoboda and his co-investigators presented findings on the safety and efficacy of armored huCART19-IL18 in this patient population. Key findings indicated that treatment with these armored CAR T cells is feasible and associated with an acceptable safety profile. Impressively, 81% (90% CI, 62%-93%) of patients achieved aresponse, with 52% (90% CI, 33%-71%) achieving complete responses, including patients who were refractory to currently available second-generation CAR T-cell therapies.

The trial’s results showed durable remissions lasting over 2 years in some patients, highlighting the potential effectiveness of targeting CD19 in lymphoma after prior CAR T-cell therapy. Researchers also noted that the efficacy did not significantly vary with different dose levels.

This type of first-in-human trial primarily focuses on safety, but one of the secondary objectives of this study was to evaluate the preliminary efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas, Svoboda begins, noting that investigators were encouraged by the performance of these armored CAR T cells in patients who were relapsed/refractory to prior second-generation CAR T-cell therapies. Although these are early data and should be interpreted with caution, Svoboda reports that durable responses were observed. The trial was initiated over 2 years ago, and some of the initially treated patients, who were clearly refractory to the second-generation CAR T cell therapies, remain in remission, he adds. It has been remarkable to see that a single infusion of CAR T cells in these patients, whose additional treatment options are limited, can result in such long-lasting remissions, Svoboda concludes.

Related Videos
Benjamin Levy, MD
Paolo Tarantino, MD
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital